Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis

Heart

Volumn 104, Issue 13, 2018, Pages 1101-1108

  Anand, Atul ^a   Chin, Calvin ^a   Shah, Anoop S V ^a   Kwiecinski, Jacek ^a,b   Vesey, Alex ^a   Cowell, Joanna ^c   Weber, Ekkehard ^d   Kaier, Thomas ^a,e   Newby, David E ^a   Dweck, Marc ^a   Marber, Michael S ^e   Mills, Nicholas L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Royal Victoria Building ^*  (United Kingdom)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

aortic stenosis; cardiac magnetic resonance (CMR) imaging

Indexed keywords

BIOLOGICAL MARKER; MYOSIN BINDING PROTEIN C; CARRIER PROTEIN; CONTRAST MEDIUM; MYOSIN-BINDING PROTEIN C;

ADULT; AGED; ALL CAUSE MORTALITY; AORTIC STENOSIS; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CELL DEATH; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY CALCIUM SCORE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE MASS; HEART MUSCLE BIOPSY; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; AORTIC VALVE STENOSIS; BLOOD; CARDIAC MUSCLE; CARDIOMEGALY; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; FIBROSIS; HEART VENTRICLE REMODELING; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; BIOMARKERS; CARDIOMEGALY; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL DEATH; CONTRAST MEDIA; FEMALE; FIBROSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VENTRICULAR REMODELING;

EID: 85047154260     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2017-312257     Document Type: Article

References (30)

1. Osnabrugge RLJ, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly. J Am Coll Cardiol 2013;62:1002-12.
2. Dweck MR, Joshi S, Murigu T, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol 2011;58:1271-9.
3. Dweck MR, Joshi S, Murigu T, et al. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:50.
4. C ioffi G, Faggiano P, Vizzardi E, et al. Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart 2011;97:301-7.
5. H ein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984-91.
6. C hin CW, Shah AS, McAllister DA, et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J 2014;35:2312-21.
7. Baker JO, Tyther R, Liebetrau C, et al. Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury. Basic Res Cardiol 2015;110:23.
8. Jacquet S, Yin X, Sicard P, et al. Identification of cardiac myosin-binding protein C as a candidate biomarker of myocardial infarction by proteomics analysis. Mol Cell Proteomics 2009;8:2687-99.
9. Marjot J, Liebetrau C, Goodson RJ, et al. The development and application of a high-sensitivity immunoassay for cardiac myosin-binding protein C. Transl Res 2016;170:17-25.
10. A ye TT, Scholten A, Taouatas N, et al. Proteome-wide protein concentrations in the human heart. Mol Biosyst 2010;6:1917-27.
11. Barefield D, Sadayappan S. Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol 2010;48:866-75.
12. Marjot J, Kaier TE, Martin ED, et al. Quantifying the release of biomarkers of myocardial necrosis from cardiac myocytes and intact myocardium. Clin Chem 2017;63:990-6.
13. Van Driest SL, Ommen SR, Tajik AJ, et al. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc 2005;80:463-9.
14. G upta MK, Robbins J. Post-translational control of cardiac hemodynamics through myosin binding protein C. Pflugers Arch 2014;466:231-6.
15. R azzaque MA, Gupta M, Osinska H, et al. An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure. Circ Res 2013;113:553-61.
16. Kaier TE, Twerenbold R, Puelacher C, et al. Direct comparison of cardiac myosinbinding protein c with cardiac troponins for the early diagnosis of acute myocardial infarction. Circulation 2017;136:1495-508.
17. S hah AS, Chin CW, Vassiliou V, et al. Left ventricular hypertrophy with strain and aortic stenosis. Circulation 2014;130:1607-16.
18. C hin CW, Messika-Zeitoun D, Shah AS, et al. A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis. Eur Heart J 2016;37:713-23.
19. C hin CW, Semple S, Malley T, et al. Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging 2014;15:556-65.
20. S ingh A, Horsfield MA, Bekele S, et al. Myocardial T1 and extracellular volume fraction measurement in asymptomatic patients with aortic stenosis: reproducibility and comparison with age-matched controls. Eur Heart J Cardiovasc Imaging 2015;16:763-70.
21. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 2009;10:1-25.
22. C owell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
23. H ouslay ES, Cowell SJ, Prescott RJ, et al. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart 2006;92:1207-12.
24. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:867-74.
25. Vigliano CA, Cabeza Meckert PM, Diez M, et al. Cardiomyocyte hypertrophy, oncosis, and autophagic vacuolization predict mortality in idiopathic dilated cardiomyopathy with advanced heart failure. J Am Coll Cardiol 2011;57:1523-31.
26. S aito T, Hojo Y, Hirose M, et al. High-sensitivity troponin T is a prognostic marker for patients with aortic stenosis after valve replacement surgery. J Cardiol 2013;61:342-7.
27. Kupari M, Eriksson S, Turto H, et al. Leakage of cardiac troponin I in aortic valve stenosis. J Intern Med 2005;258:231-7.
28. Quarto C, Dweck MR, Murigu T, et al. Late gadolinium enhancement as a potential marker of increased perioperative risk in aortic valve replacement. Interact Cardiovasc Thorac Surg 2012;15:45-50.
29. T reibel TA , López B, González A, et al. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J 2017;12:1.
30. A pple FS, Collinson PO. IFCC Task force on clinical applications of cardiac biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clinical Chemistry 2012;58:54-61.